RHUMBLINE ADVISERS - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 40 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q2 2013. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q1 2019$97,000
+18.3%
72,696
-0.4%
0.00%
Q4 2018$82,000
-42.7%
72,976
+40.6%
0.00%
Q3 2018$143,000
-22.3%
51,887
+0.6%
0.00%
Q2 2018$184,000
+25.2%
51,587
+7.6%
0.00%
Q1 2018$147,000
-56.9%
47,962
-11.5%
0.00%
-100.0%
Q4 2017$341,000
-13.5%
54,187
-5.9%
0.00%0.0%
Q3 2017$394,000
+7.1%
57,593
+11.5%
0.00%0.0%
Q2 2017$368,000
-18.0%
51,633
+5.7%
0.00%0.0%
Q1 2017$449,000
+162.6%
48,853
+14.9%
0.00%
Q4 2016$171,000
-21.6%
42,512
-25.3%
0.00%
-100.0%
Q3 2016$218,000
-11.7%
56,945
-0.9%
0.00%0.0%
Q2 2016$247,000
+39.5%
57,435
+50.1%
0.00%0.0%
Q1 2016$177,000
-53.1%
38,255
+1.8%
0.00%0.0%
Q4 2015$377,000
+49.0%
37,575
+10.8%
0.00%0.0%
Q3 2015$253,000
-83.8%
33,915
+3.1%
0.00%
-80.0%
Q2 2015$1,561,000
+71.4%
32,906
+32.4%
0.01%
+66.7%
Q1 2015$911,000
+14.3%
24,856
+23.8%
0.00%
+50.0%
Q4 2014$797,000
+133.0%
20,081
+17.2%
0.00%
+100.0%
Q3 2014$342,000
+48.1%
17,1310.0%0.00%0.0%
Q2 2014$231,000
+102.6%
17,131
+63.9%
0.00%
Q1 2014$114,000
+62.9%
10,453
+4.3%
0.00%
Q2 2013$70,00010,0200.00%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q2 2013
NameSharesValueWeighting ↓
HARVEY CAPITAL MANAGEMENT INC 354,300$7,068,0002.77%
Opaleye Management Inc. 169,700$3,385,515,0002.64%
Broadfin Capital, LLC 959,247$19,137,0002.01%
Novo Holdings A/S 900,000$17,955,0001.75%
Eventide Asset Management 300,900$6,003,0000.84%
EAM Investors, LLC 152,595$3,044,0000.62%
COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT 497,858$9,932,0000.51%
Granite Point Capital Management, L.P. 40,000$798,0000.40%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 450,191$8,981,0000.33%
TFS CAPITAL LLC 133,070$2,655,0000.23%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders